Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose

GlobeNewswire September 27, 2018

Ultragenyx to Present at Jefferies Gene Therapy Summit

GlobeNewswire September 26, 2018

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

GlobeNewswire September 17, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2018

Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders

GlobeNewswire August 29, 2018

Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII

GlobeNewswire August 27, 2018

Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

GlobeNewswire August 2, 2018

Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results and Corporate Update

GlobeNewswire July 27, 2018

Ultragenyx Announces First Patient Dosed in Phase 1/2 study of DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa); FDA Grants Fast Track Designation to Gene Therapy Program

GlobeNewswire July 26, 2018

Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII

GlobeNewswire June 29, 2018

Report: Developing Opportunities within Spartan Motors, Ultragenyx Pharmaceutical, Advanced Energy Industries, Verisk Analytics, Cogent Communications, and ADTRAN — Future Expectations, Projections Moving into 2018

GlobeNewswire June 19, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire June 4, 2018

Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings

Benzinga.com  May 24, 2018

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

GlobeNewswire May 23, 2018

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)

GlobeNewswire May 17, 2018

Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 7, 2018

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call

Accesswire May 7, 2018

Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update

GlobeNewswire May 1, 2018

Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults

GlobeNewswire April 30, 2018

Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X–Linked Hypophosphatemia (XLH)

GlobeNewswire April 17, 2018